Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.
Read more on News-Medical-Net
Orignal From: Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark
Post a Comment